RenÃ©e G Stark

List of Publications by Year
in descending order

38 papers	1,566 citations	430874 18 h-index	302126 39 g-index
40 all docs	40 docs citations	40 times ranked	2708 citing authors

#	Article	IF	Citations
1	Following Pediatric and Adult IBD Patients through the COVID-19 Pandemic: Changes in Psychosocial Burden and Perception of Infection Risk and Harm over Time. Journal of Clinical Medicine, 2021, 10, 4124.	2.4	7
2	Assessment of excess medical costs for persons with type 2 diabetes according to age groups: an analysis of German health insurance claims data. Diabetic Medicine, 2020, 37, 1752-1758.	2.3	9
3	Impact of interventions to reduce overnutrition on healthcare costs related to obesity and type 2 diabetes: a systematic review. Nutrition Reviews, 2020, 78, 412-435.	5.8	5
4	Health related quality of life associated with extreme obesity in adolescents – results from the baseline evaluation of the YES-study. Health and Quality of Life Outcomes, 2020, 18, 58.	2.4	10
5	Do adolescents with extreme obesity differ according to previous treatment seeking behavior? The Youth with Extreme obesity Study (YES) cohort. International Journal of Obesity, 2019, 43, 103-115.	3.4	11
6	Cost-effectiveness of increasing the reach of smoking cessation interventions in Germany: results from the EQUIPTMOD. Addiction, 2018, 113, 52-64.	3.3	6
7	A Walnut-Enriched Diet Affects Gut Microbiome in Healthy Caucasian Subjects: A Randomized, Controlled Trial. Nutrients, 2018, 10, 244.	4.1	82
8	Current health status and medical therapy of patients with pediatric-onset inflammatory bowel disease. European Journal of Gastroenterology and Hepatology, 2017, 29, 1276-1283.	1.6	8
9	A Walnut-Enriched Diet Reduces Lipids in Healthy Caucasian Subjects, Independent of Recommended Macronutrient Replacement and Time Point of Consumption: a Prospective, Randomized, Controlled Trial. Nutrients, 2017, 9, 1097.	4.1	41
10	The Non-Linear Relationship between BMI and Health Care Costs and the Resulting Cost Fraction Attributable to Obesity. International Journal of Environmental Research and Public Health, 2017, 14, 984.	2.6	16
11	The Economic Burden of Obesity in Germany: Results from the Population-Based KORA Studies. Obesity Facts, 2016, 9, 397-409.	3.4	38
12	Cost burden of type 2 diabetes in Germany: results from the population-based KORA studies. BMJ Open, 2016, 6, e012527.	1.9	50
13	The effectiveness of German disease management programs (DMPs) in patients with type 2 diabetes mellitus and coronary heart disease: results from an observational longitudinal study. Diabetology and Metabolic Syndrome, 2015, 7, 77.	2.7	19
14	Towards Patient-Oriented Diabetes Care: Results from Two KORA Surveys in Southern Germany. Journal of Diabetes Research, 2015, 2015, 1-14.	2.3	14
15	The Burden of Diabetes Mellitus in Patients with Coronary Heart Disease: A Methodological Approach to Assess Quality-Adjusted Life-Years Based on Individual-Level Longitudinal Survey Data. Value in Health, 2015, 18, 969-976.	0.3	12
16	Effects of Metformin on Metabolite Profiles and LDL Cholesterol in Patients With Type 2 Diabetes. Diabetes Care, 2015, 38, 1858-1867.	8.6	97
17	Improving care of post-infarct patients: effects of disease management programmes and care according to international guidelines. Clinical Research in Cardiology, 2014, 103, 237-245.	3.3	16
18	Walnut-enriched diet reduces fasting non-HDL-cholesterol and apolipoprotein B in healthy Caucasian subjects: A randomized controlled cross-over clinical trial. Metabolism: Clinical and Experimental, 2014, 63, 382-391.	3.4	75

#	Article	IF	Citations
19	Medication Costs by Glucose Tolerance Stage in Younger and Older Women and Men: Results from the Population-based KORA Survey in Germany. Experimental and Clinical Endocrinology and Diabetes, 2013, 121, 614-623.	1.2	3
20	Drug Costs in Prediabetes and Undetected Diabetes Compared With Diagnosed Diabetes and Normal Glucose Tolerance: Results From the Population-Based KORA Survey in Germany. Diabetes Care, 2013, 36, e53-e54.	8.6	13
21	Less Advanced Stages of Colon Cancer in Patients with Type 2 Diabetes Mellitus: an Unexpected Finding?. Experimental and Clinical Endocrinology and Diabetes, 2012, 120, 224-228.	1.2	8
22	The Performance of a Value Set for the EQ-5D Based on Experienced Health States in Patients with Inflammatory Bowel Disease. Value in Health, 2012, 15, 151-157.	0.3	16
23	Health care use and costs of adverse drug events emerging from outpatient treatment in Germany: A modelling approach. BMC Health Services Research, 2011, 11, 9.	2.2	38
24	Medical care of type 2 diabetes in German Disease Management Programmes: a population‐based evaluation. Diabetes/Metabolism Research and Reviews, 2011, 27, 383-391.	4.0	31
25	High-Dose Treatment With Telmisartan Induces Monocytic Peroxisome Proliferator-Activated Receptor-Î³ Target Genes in Patients With the Metabolic Syndrome. Hypertension, 2011, 58, 725-732.	2.7	31
26	Validity, reliability, and responsiveness of the EQ-5D in inflammatory bowel disease in Germany. Inflammatory Bowel Diseases, 2010, 16, 42-51.	1.9	83
27	Metabolic syndrome predicts vascular changes in whole body magnetic resonance imaging in patients with long standing diabetes mellitus. Cardiovascular Diabetology, 2010, 9, 44.	6.8	7
28	In Germany Diabetic Patients with Coronary Artery Disease are Treated More Intensively than Diabetic Patients with Other Manifestations of Atherothrombosis â€" Results from the REACH Registry. Experimental and Clinical Endocrinology and Diabetes, 2010, 118, 51-56.	1.2	5
29	Low Adiponectin Levels Are an Independent Predictor of Mixed and Non-Calcified Coronary Atherosclerotic Plaques. PLoS ONE, 2009, 4, e4733.	2.5	55
30	Chemerin is associated with markers of inflammation and components of the metabolic syndrome but does not predict coronary atherosclerosis. European Journal of Endocrinology, 2009, 161, 339-344.	3.7	257
31	PDB60 EVALUATION OF THE PATIENT'S PERSPECTIVE OF MEDICAL CARE IN TYPE 2 DIABETES DISEASE MANAGEMENT PROGRAMS. Value in Health, 2009, 12, A412-A413.	0.3	0
32	Systemic Cardiovascular Complications in Patients With Long-Standing Diabetes Mellitus. Investigative Radiology, 2009, 44, 242-250.	6.2	44
33	CXCL16 is a surrogate marker of inflammatory bowel disease. Scandinavian Journal of Gastroenterology, 2008, 43, 283-288.	1.5	26
34	Resistin is an inflammatory marker of inflammatory bowel disease in humans. European Journal of Gastroenterology and Hepatology, 2007, 19, 1070-1074.	1.6	128
35	Apolipoprotein A-IV Is an Independent Predictor of Disease Activity in Patients with Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2007, 13, 391-397.	1.9	17
36	Costs of Inflammatory Bowel Disease in Germany. Pharmacoeconomics, 2006, 24, 797-814.	3.3	110

#	Article	IF	Citations
37	Effect of ultrasound screening on the rate of first operative procedures for developmental hip dysplasia in Germany. Lancet, The, 2003, 362, 1883-1887.	13.7	143
38	Assessment of Value of Glycosylated Albumin and Protein in Detection of Gestational Diabetes. Diabetes Care, 1987, 10, 213-216.	8.6	18